Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line

Toxicology and Applied Pharmacology

Volumn 216, Issue 1, 2006, Pages 89-97

  Vaskivuo, Liisa ^a   Rysä, Jaana ^a   Koivuperä, Johanna ^a   Myllynen, Päivi ^a   Vaskivuo, Tommi ^a   Chvalova, Katerina ^b   Serpi, Raisa ^a   Savolainen, Eeva Riitta ^a   Puistola, Ulla ^a   Vähäkangas, Kirsi ^a,b  

^a UNIVERSITY OF OULU   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Azidothymidine; Cisplatin; Docetaxel; p14ARF; p53

Indexed keywords

CISPLATIN; DOCETAXEL; MUTANT PROTEIN; MYC PROTEIN; PROTEIN P14ARF; PROTEIN P53; ZIDOVUDINE;

ARTICLE; BREAST CARCINOMA; CARCINOMA CELL; CELL DEATH; COLON CARCINOMA; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; ONCOGENE H RAS; OVARY CANCER; OVARY CARCINOMA; PROTEIN EXPRESSION; WILD TYPE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CISPLATIN; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; RAS PROTEINS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, MESSENGER; SALIVARY ALPHA-AMYLASES; TAXOIDS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53; ZIDOVUDINE;

EID: 33748748896     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2006.04.015     Document Type: Article

References (56)

1. Baptiste N., and Prives C. p53 in the cytoplasm: a question of overkill?. Cell 116 (2004) 487-489
2. Barnas C., Martel-Planche G., Furukawa Y., Hollstein M., Montesano R., and Hainaut P. Inactivation of the p53 protein in cell lines derived from human esophageal cancers. Int. J. Cancer 71 (1997) 79-87
3. Bazarbachi A., Nasr R., El-Sabban M.E., Mahe A., Mahieux R., Gessain A., Darwiche N., Dbaibo G., Kersual J., Zermati Y., Dianoux L., Chelbi-Alix M.K., de The H., and Hermine O. Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-1 associated adult T cell leukemia/lymphoma. Leukemia 14 (2000) 716-721
4. Bialkowska A., Bialkowski K., Gerschenson M., Diwan B.A., Jones A.B., Olivero O.A., Poirier M.A., Anderson L.M., Kasprzak K.S., and Sipowicz M.A. Oxidative DNA damage in fetal tissues after transplacental exposure to 3′-azido-3′-deoxythymidine (AZT). Carcinogenesis 21 (2000) 1059-1062
5. Cassinelli G., Supino R., Perego P., Polizzi D., Lanzi C., Pratesi G., and Zunino F. A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes. Int. J. Cancer 92 (2001) 738-747
6. Chin L., Pomerantz J., and DePinho R.A. The INK4a/ARF tumor suppressor: one gene-two products-two pathways. Trends Biochem. Sci. 23 (2003) 291-296
7. Cinatl Jr. J., Kotchetkov R., Groschel B., Cinatl J., Driever P.H., Kabickova H., Kornhuber B., Schwabe D., and Doerr H.W. Azidothymidine resistance of H9 human T-cell lymphoma cells is associated with decreased sensitivity to antitumor agents and inhibition of apoptosis. Int. J. Mol. Med. 2 (1998) 685-691
8. Collins C.J., and Sedivy J.M. Involvement of the INK4a/Arf gene locus in senescence. Aging Cell 2 (2003) 145-150
9. Darnowski J.W., Davol P.A., and Goulette F.A. Human recombinant interferon alpha-2a plus 3′-azido-3′-deoxythymidine. Synergistic growth inhibition with evidence of impaired DNA repair in human colon adenocarcinoma cells. Biochem. Pharmacol. 53 (1997) 571-580
10. de Molina A.R., Rodríguez-González A., and Lacal J.C. From Ras signaling to ChoK inhibitors: a further advance in anticancer drug design. Cancer Lett. 206 (2004) 137-148
11. Deng X., Kim M., Vandier D., Jung Y., Rikiyama T., Sgagias M.K., Goldsmith M., and Cowan K.H. Recombinant adenovirus-mediated p14ARF overexpression sensitizes human breast cancer cells to cisplatin. Biochem. Biophys. Res. Commun. 296 (2002) 792-798
12. Elliott M.J., Dong Y.B., Yang H., and McMasters K.M. E2F-1 up-regulates c-Myc and p14(ARF) and induces apoptosis in colon cancer cells. Clin. Cancer Res. 7 (2001) 3590-3597
13. Gao N., Hu Y.D., Cao X.Y., Zhou J., and Cao S.L. The exogenous wild-type p14ARF gene induces growth arrest and promotes radiosensitivity in human lung cancer cell lines. J. Cancer Res. Clin. Oncol. 127 (2001) 359-367
14. Guimaraes D.P., and Hainaut P. TP53: a key in human cancer. Biochimie 84 (2002) 83-93
15. Guo-Chang F., and Chu-Tse W. Transfer of p14ARF gene in drug-resistant human breast cancer MCF-7/Adr cells inhibits proliferation reduces doxorubicin resistance. Cancer Lett. 158 (2000) 203-210
16. Hainaut P., and Vähäkangas K. p53 as a sensor of carcinogenic exposures: mechanisms of p53 protein induction and lessons from p53 gene mutations. Pathol. Biol. (Paris) 45 (1997) 833-844
17. Haupt S., Berger M., Goldberg Z., and Haupt Y. Apoptosis-The p53 network. J. Cell Sci. 116 (2003) 4077-4085
18. Imamura T., Izumi H., Nagatani G., Ise T., Nomoto M., Iwamoto Y., and Kohno K. Interaction with p53 enhances binding of cisplatin-modified DNA by mobility group 1 protein. J. Biol. Chem. 276 (2001) 7534-7540
19. Iwamoto T., Hiraku Y., Oikawa S., Mizutani H., Kojima M., and Kawanishi S. Oxidative DNA damage induced by photodegradation products of 3′-azido-3′-deoxythymidine. Arch. Biochem. Biophys. 416 (2003) 155-163
20. Khan S.H., Moritsugu J., and Wahl G.M. Different requirement of p19ARF in the p53-dependent arrest induced by DNA damage, microtubule disruption, and ribonucleotide depletion. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 3266-3271
21. Khan S., Guevara C., Fujii G., and Parry D. p14ARF is a component of the p53 response following ionizing irradiation of normal human fibroblasts. Oncogene 23 (2004) 6040-6046
22. Kolfschoten G.M., Hulscher T.M., Duyndam M.C.A., Pinedo H.M., and Boven E. Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel. Biochem. Pharmacol. 63 (2002) 733-743
23. Korgaonkar C., Zhao L., Modestou M., and Quelle D.E. ARF function does not require p53 stabilization or Mdm2 relocalization. Mol. Cell. Biol. 22 (2002) 196-206
24. Latonen L., Kurki S., Pitkänen K., and Laiho M. p53 and MDM2 are regulated by PI-3-kinases on multiple levels under stress induced by UV radiation and proteasome dysfunction. Cell Signalling 15 (2002) 95-102
25. Lavarino C., Pilotti S., Oggionni M., Gatti L., Perego P., Bresciani G., Pierotti M.A., Scambia G., Ferrandina G., Fagotti A., Mangioni C., Lucchini V., Vecchione F., Bolis G., Scarfone G., and Zunino F. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J. Clin. Oncol. 18 (2000) 3936-3945
26. Lee C., Smith B.A., Bandyopadhyay K., and Gjerset R.A. DNA damage disrupts the 14ARF-B23(nucleophosmin) interaction and triggers a transient subnuclear redistribution of p14ARF. Cancer Res. 65 (2005) 9834-9842
27. Lengyel E., Stepp E., Gum R., and Boyd D. Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras. J. Biol. Chem. 270 (1995) 23007-23012
28. Mediavilla M.D., and Sánchez-Barceló E.J. Doses and time-dependent effects of 3′-azido-3′-deoxythymidine on T47D human breast cancer cells in vitro. Pharmacol. Toxicol. 87 (2000) 138-143
29. Melana S.M., Holland J.F., and Pogo B.G. Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3′-azido-3′-deoxythymidine. Clin. Cancer Res. 4 (1998) 693-696
30. Mo Y., Gan Y., Song S., Johnston J., Xiao X., Wientjes M.G., and Au J.L. Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res. 63 (2003) 579-585
31. Modica-Napolitano J.S., Nalbandian R., Kidd M.E., Nalbandian A., and Nguyen C.C. The selective in vitro cytotoxicity of carcinoma cells by AZT is enhanced by concurrent treatment with lipophilic cations. Cancer Lett. 198 (2003) 59-68
32. Moll U.M., and Petrenko O. The MDM2-p53 interaction. Mol. Cancer Res 1 (2003) 1001-1008
33. Morgan R.J., Newman E.M., Sowers L., Scanlon K., Harrison J., Akman S., Leong L., Margolin K., Niland J., Raschko J., Somlo G., Carroll M., Chow W., Tetef M., Hamasaki V., Yen Y., and Doroshow J.H. Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies. Cancer Chemother. Pharmacol. 51 (2003) 459-464
34. Olivero O.A., and Poirier M.C. Preferential incorporation of 3′-azido-2′,3′-dideoxythymidine into telomeric DNA and Z-DNA-containing regions of Chinese hamster ovary cells. Mol. Carcinog. 8 (1993) 81-88
35. Olivero O.A., Parikka R., Poirier M.C., and Vähäkangas K. 3′Azido-3′-deoxythymidine (AZT) transplacental perfusion kinetics and DNA incorporation in normal human placentas perfused with AZT. Mutat. Res. 428 (1999) 41-47
36. Pluquet O., and Hainaut P. Genotoxic and non-genotoxic pathways of p53 induction. Cancer Lett. 174 (2001) 1-15
37. Poirier M.C., Olivero O.A., Walker D.M., and Walker V.E. Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs. Toxicol. Appl. Pharmacol. 199 (2004) 151-161
38. ARF directly and differentially controls the functions of c-Myc independently of p53. Nature 431 (2004) 712-717
39. Romieu-Mourez R., Landesman-Pollag E., Seldin D.C., and Sonenshein G.E. Protein kinase CK2 promotes aberrant activation of nuclear factor-κB, transformed phenotype, and survival of breast cancer cells. Cancer Res. 62 (2002) 6770-6778
40. Rysä J., Leskinen H., Ilves M., and Ruskoaho H. Distinct upregulation of extracellular matrix genes in transition from hypertrophy to hypertensive heart failure. Hypertension 45 (2005) 927-933
41. Rämet M., Castren K., Järvinen K., Pekkala K., Turpeenniemi-Hujanen T., Soini Y., Pääkkö P., and Vähäkangas K. p53 expression is correlated with benzo(a)pyrene-DNA adducts in carcinoma cell lines. Carcinogenesis 16 (1995) 2117-2124
42. Scanlon K.J., Funato T., Pezeshki B., Tone T., and Sowers L.C. Potentiation of azidothymidine cytotoxicity in cisplatin-resistant human ovarian carcinoma cells. Cancer Commun. 2 (1990) 339-343
43. Schuijer M., and Berns E.M.J.J. TP53 and ovarian cancer. Hum. Mutat. 21 (2003) 285-291
44. Secombe J., Pierce S.B., and Eisenman N. Myc: a weapon of mass destruction. Cell 117 (2004) 153-156
45. Sengupta S., and Harris C.C. p53: traffic cop at the crossroads of DNA repair and recombination. Nat. Rev., Mol. Cell Biol. 6 (2005) 44-55
46. Serpi R., Piispala J., Järvilehto M., and Vähäkangas K. Thapsigargin has similar effect on p53 protein response to benzo(a)pyrene-DNA adducts as TPA in mouse skin. Carcinogenesis 20 (1999) 1755-1760
47. Sheikh M.S., Hollander M.C., and Fornance Jr. A.J. Role of Gadd45 in apoptosis. Biochem. Pharmacol. 59 (2000) 43-45
48. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22 (2003) 7265-7279
49. Stott F.J., Bates S., James M.C., McConnell B.B., Starborg M., Brookes S., Palmero I., Ryan K., Hara E., Vousden K.H., and Peters G. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17 (1998) 5001-5014
50. Turpeinen M., Serpi R., Rahkolin M., and Vähäkangas K. Comparison of anti-p53 antibodies in immunoblotting. Biochem. Biophys. Res. Commun. 293 (2002) 850-856
51. Tuschl H., and Schwab C.E. Flow cytometric methods used as screening tests for basal toxicity of chemicals. Toxicol. In Vitro. 18 (2004) 483-491
52. Vousden K.H. Activation of the p53 tumor suppressor protein. Biochim. Biophys. Acta. 1602 (2002) 47-59
53. Wagner C.R., Ballato G., Akanni A.O., McIntee E.J., Larson R.S., Chang S., and Abul-Hajj Y.J. Potent growth inhibitory activity of zidovudine on cultured human breast cancer cells and rat mammary tumors. Cancer Res. 57 (1997) 2341-2345
54. Wahl A.F., Donaldson K.L., Fairchild C., Lee F.Y., Foster S.A., Demers G.W., and Galloway D.A. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat. Med. 2 (1996) 72-79
55. Wang L.G., Liu X.M., Kreis W., and Budman D.R. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother. Pharmacol. 44 (1999) 355-361
56. Zindy F., Eischen C.M., Randle D.H., Kamijo T., Cleveland J.L., Sherr C.J., and Roussel M.F. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12 (1998) 2424-2433